Depo-Provera Lawsuit Settlement Reached
Eligible plaintiffs have until November 30, 2026, to register for a settlement regarding potential meningioma risks.
Updated on Oct. 22, 2026 in Alzheimer’s
Live Poll
Do you trust that pharmaceutical companies adequately warn patients about the potential long-term risks of medications?
Pfizer reached a settlement agreement in June 2026 to resolve federal and New York state lawsuits alleging that the contraceptive Depo-Provera is linked to an increased risk of developing meningiomas. Eligible claimants must register for the settlement by November 30, 2026.
Why it matters
This settlement addresses legal claims that the manufacturer failed to adequately warn users about the potential risk of intracranial tumors. While the company admits no wrongdoing, the agreement establishes a framework to resolve the majority of pending federal litigation regarding these health concerns.
Official federal filings as of October 1, 2026, indicate that 6,412 lawsuits have been centralized in the Northern District of Florida. Approximately 80% of these cases are expected to be resolved through this settlement, while 1,280 cases currently remain excluded.
The players
Pfizer
A global pharmaceutical company that manufactures Depo-Provera and various other medications.
M. Casey Rodgers
The federal judge presiding over the centralized multidistrict litigation in the Northern District of Florida.
The details
The litigation centers on allegations that Depo-Provera use may correlate with the development of meningiomas, which are typically benign tumors that form on the membranes covering the brain and spinal cord. The Master Settlement Agreement, signed in July 2026, provides a process for resolving claims in federal court and New York state courts without an admission of liability from Pfizer. The cases were previously organized into a multidistrict litigation (MDL No. 3140) to streamline the discovery process.
Timeline
February 2025: Multidistrict litigation (MDL No. 3140) was established.
June 15, 2026: Attorneys announced the settlement agreement.
July 2026: The parties signed the Master Settlement Agreement.
October 1, 2026: 6,412 federal lawsuits were pending.
November 30, 2026: Registration deadline for eligible claimants.
Health Landscape
This settlement follows the consolidation of claims under MDL No. 3140, a common legal mechanism used to handle widespread product liability cases in the United States. It reflects a broader trend of resolving large-scale health-related litigation involving long-term medication side effects.
Individuals who have used this contraceptive and have concerns about their long-term health, including any unexplained neurological symptoms, should consult their physician. Patients involved in or considering potential claims should note the November 30, 2026, registration deadline for the settlement.
The takeaway
This settlement highlights the importance of maintaining thorough health records when reporting medication-related side effects to your doctor. If you suspect your health has been impacted by a prescribed treatment, discuss these concerns with your physician to ensure proper monitoring and documentation.
What happens next
Eligible claimants must register for the settlement by November 30, 2026.
Further reading
For additional context on how the healthcare system addresses complex medical concerns, visit our section on Alzheimer’s.
Live Poll
Do you trust that pharmaceutical companies adequately warn patients about the potential long-term risks of medications?
